SK Bioscience Secures $2.7M Grant to Advance RSV Antibody Development
South Korean biopharmaceutical company, SK Bioscience, announced Wednesday it has received a significant funding boost from the Research Investment for Global Health Technology Foundation (RIGHT Foundation). This investment will accelerate the clinical development of RSM01, a promising monoclonal antibody candidate designed to prevent respiratory syncytial virus (RSV) infections and further solidify SK Bioscience’s position in the global infectious disease market.
The RIGHT Foundation has committed 4 billion won ($2.7 million) – the largest grant amount awarded per project by the foundation – to SK Bioscience. This financial support will enable the company to expedite the Phase 1b clinical trial of RSM01, focusing on its efficacy and safety in infants, a particularly vulnerable population for RSV.
SK Bioscience previously acquired the licensing rights for RSM01 from the Gates Medical Research Institute (Gates MRI), a nonprofit biotechnology organization supported by the Bill & Melinda Gates Foundation. Adimab, a US-based firm, and the Gates MRI collaborated on the initial design and early research phases of the monoclonal antibody candidate, successfully completing a Phase 1a clinical trial.
RSM01 is being developed to offer seasonal protection against RSV through a single dose administered to newborns and infants. Preclinical studies have demonstrated the antibody’s effectiveness in inhibiting viral infection and replication. Furthermore, Phase 1a trials conducted on adults have indicated favorable safety, tolerability, and durability profiles, aligning with the intended design of the antibody.
The licensing agreement grants SK Bioscience exclusive global commercialization rights for RSM01, with the exception of India and countries supported by Gavi, the Vaccine Alliance. The company plans to pursue a dual strategy, maximizing commercial value in developed markets while simultaneously ensuring affordable access in low-income countries through large-scale manufacturing capabilities.
According to market analysis by Evaluate Pharma, the global market for RSV preventive antibodies is projected to reach $4.5 billion by 2032. This growth is expected to be driven by expanding immunization programs and the limited availability of effective treatment options currently available.
“This funding agreement underscores the potential of the technology licensed from the Gates MRI and reaffirms our dedication to safeguarding global public health,” stated Park Jin-seon, Chief Operating Officer of SK Bioscience.
“By leveraging SK Bioscience’s world-class research and development, and manufacturing expertise, we are committed to developing a globally competitive product that addresses a significant unmet medical need.”
hwkan
